Angel Biotechnology Hldgs (ABH 0.245p / 5.05m)
Angel, the contract manufacturer specialising in stem cells and complex biotech, producing low volume but extremely high grade materials announced that it has signed two new contracts with Reneuron Group. Under these contracts Angel will manufacture material to support Reneuron’s clinical trials for which it recently gained final ethical approvals for its work in stroke patients. This demonstrates the high value, complex work that Angel can complete, making it a leading GMP (Good Manufacturing Process) manufacturer.
After the recent placing in February, Angel are now funded for future growth and we think that the low share price is an excellent opportunity to participate in this exciting story, without taking on the risk usually associated with biotech (as manufacturer Angel gets paid for its work, whether the treatments are ultimately successful or not).
Cello Group (CLL 30p/ £17.56m)
Cello, the market research and consulting group, has reported prelims to 31 December 2009. LfL operating income was down 7 per cent to £60.5m, PBT down 40 per cent to £5.0m (2008: £7.0m) and EPS down 44 per cent to 7.28p (2008: 13.08p) – in line with market consensus. The company’s strong cash generation reduced net debt to £11.5m and positive trading momentum and a reduction in the cost base has led to an increase DPS by 4 per cent to 1.3p. The company reported that strong trading in the final quarter of its year has continued into the current period with good revenue pipelines and marked increases in levels of new business activity. The market forecasts 2010 PBT of £5.6m, EPS of 6.1p and DPS of 1.3p. With the stock on a 2010 P/E ratio of 4.5x we think this is one fiddle worth a play.
Cryo-Save Group (CRYO 495p / 45.71m)
The provider of storage for stem cells which are taken at birth and saved for potential use in future medical treatment announced strong growth and a positive set of year end results. Stem cell therapy is currently common practice in 70 - 85 diseases.
The private stem cell bank now has over 120,000 samples currently stored, which is approximately 50 per cent market share in Europe. Cryo-Save has operations in 38 countries across Europe, Asia and…
